CAR-T cell therapy is now FDA-approved for patients with ALL and non-Hogkin lymphoma. Penn is currently enrolling appropriate patients with other forms of cancer into CAR-T clinical trials.
CAR-T for Pediatric and Young Adult Leukemia
With the FDA approval of our CAR-T cell therapy, Kymriah™, we are able to treat adults, ages 18 to 25, with acute lymphoblastic leukemia (ALL). For more information or to schedule a consultation, please call 215-316-5127.
If you or a loved one has ALL and is under 18 years old, Children’s Hospital of Philadelphia (CHOP) may be able to help. You can reach the Cancer Immunotherapy Program at CHOP at 267-426-0762.
Take a look at this short video, produced by Ross Kauffman, which details the story of the first pediatric patient to receive our CAR-T cell therapy:
CAR-T for Non-Hogkin Lymphoma
The FDA recently approved Yescarta™ (axicabtagene ciloleucel), a CAR-T cell therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, and we will soon be able to administer it.
Please call 215-316-5127 to make an appointment with a Penn oncologist who is expert in treating patients with B cell lymphoma and other types of cancer.
CAR-T for Other Cancers
Our success in personalized cellular therapy does not stop with leukemia and lymphoma. We are continuing to develop and test cancer vaccines, immune modulatory drugs and cell-based therapies for both blood and solid tumor cancers.
There are a number of CAR-T cell therapy clinical trials available at Penn Medicine for all different forms of cancer. View the list here.
To learn more about clinical trials, watch our video What Is A Clinical Trial?